SUNRISE, Fla., Oct. 4, 2011 (GLOBE NEWSWIRE) -- www.bioheartinc.com/">Bioheart, Inc. (OTCBB:BHRT), announced today that their clinical paper has been published in a prominent peer reviewed medical journal. "A Double-blind, Randomized, Controlled, Multicenter Study to Assess the Safety and Cardiovascular Effects of Skeletal Myoblast Implantation by Catheter Delivery in Patients with Chronic Heart Failure Following Myocardial Infarction" was published online in the American Heart Journal on September 12, 2011.
MARVEL is the first blinded placebo-controlled trial assessing the safety and efficacy of myoblast's delivered via catheter for patients with advanced symptoms of heart failure due to a heart attack. When compared with placebo, myoblast therapy was associated with sustained (6 months) improvements in six minute walk distance of >90 meters, a clinically meaningful improvement. This means that a congestive heart failure patient may return to a more active lifestyle. Some of the enrolling centers in the trial include: Minneapolis Heart Institute, Florida Hospital Center, The Lindner Center, Jim Moran Heart and Vascular Research Institute, Scripps Green Hospital, and Arizona Heart Institute.
Click here to access the article:
http://www.ahjonline.com/article/S0002-8703(11)00562-X/abstract
About Bioheart, Inc.
Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our goals are to cause damaged tissue to be regenerated, if possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, we are focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Our leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
For more information on Bioheart, visit www.globenewswire.com/newsroom/ctr%3Fd=227994%26l=7%26a=http%253A%252F%252Fwww.bioheartinc.com%26u=http%253A%252F%252Fus.lrd.yahoo.com%252F_ylt%253DAlOSZ9CEXfT3uibZcyJcgLWxcq9_%253B_ylu%253DX3oDMTE2cnJmdW9hBHBvcwMxBHNlYwNuZXdzYXJ0Ym9keQRzbGsDaHR0cHd3d2Jpb2hl%252FSIG%253D11fguppga%252FEXP%253D1312565712%252F%252A%252Ahttp%25253A%252Fwww.bioheartinc.com%252F">http://www.bioheartinc.com.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.